



ABN 53 075 582 740

**ASX ANNOUNCEMENT
2 August 2021**

Bionomics Announces Planned Capital Distribution to Shareholders

Bionomics Limited (ASX: BNO, OTCQB: BNOEF), (**Bionomics**) a global, clinical stage biopharmaceutical company, refers to its announcement to ASX today titled “**Bionomics Announces Plans to Conduct U.S. Initial Public Offering**”.

Bionomics advises that it is expecting to propose, in connection with and prior to any such proposed U.S. offering, to make a capital distribution representing an economic interest in the net after tax royalty payments (if any), received by Bionomics under its exclusive Research Collaboration and License Agreement with Merck & Co (known as MSD outside the U.S. and Canada) relating to BNC375 and related compounds. This capital distribution will be distributed as a financial asset, on a per share basis, to shareholders holding Bionomics shares on a record date to be set prior to the proposed U.S. offering. The precise form of the financial asset is yet to be determined.

Bionomics expects that the distribution, should it take place, would be implemented by way of an equal capital reduction and a scheme of arrangement, requiring shareholder and court approvals.

Bionomics will advise further information concerning the distribution in due course. There is no certainty that the distribution will take place.

Forward Looking Statements

This press release contains forward-looking statements. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our plans to propose a capital distribution and to conduct a registered initial public offering in the United States.

These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from our expectations expressed or implied by the forward-looking statements, including, but not limited to, the following: we may determine not to conduct a registered initial public offering on the time frame that we currently expect or at all, due to a number of potential important factors, including conditions in the U.S. capital markets, negative global economic conditions, potential negative developments in our clinical trials or research programs, other negative developments in our business, or unfavorable legislative or regulatory developments.

For personal use only

These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Released on authority of the Board

FOR FURTHER INFORMATION PLEASE CONTACT:

Ms Suzanne Irwin
Company Secretary
+61 8 8150 7400
Cosec@bionomics.com.au

About Bionomics Limited

Bionomics (ASX: BNO, OTCQB: BNOEF) is a clinical-stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best-in-class, novel drug candidates for patients affected by central nervous system (CNS) disorders. Bionomics' lead drug candidate BNC210 is a negative allosteric modulator of the $\alpha 7$ nicotinic acetylcholine receptor. BNC210 oral tablet formulation is currently being evaluated in a second Phase 2b trial for the treatment of Post-Traumatic Stress Disorder (PTSD) for which it was granted Fast Track designation by the FDA. BNC210 is also being evaluated as an acute treatment in Social Anxiety Disorder (SAD) patients and is expected to enter a Phase 2 trial. In addition, Bionomics has entered into a Memorandum of Understanding with EmpathBio Inc, a wholly owned subsidiary of Germany-based CNS clinical development company, atai Life Sciences, to collectively explore a combination drug treatment regimen with Bionomics' BNC210 and EmpathBio's 3,4- Methylenedioxymethamphetamine (MDMA) derivative EMP-01 for the treatment of PTSD. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer's disease.